PTC Therapeutics (NASDAQ:PTCT) Insider Neil Gregory Almstead Sells 1,279 Shares

PTC Therapeutics, Inc. (NASDAQ:PTCT) insider Neil Gregory Almstead sold 1,279 shares of PTC Therapeutics stock in a transaction that occurred on Tuesday, January 6th. The shares were sold at an average price of $76.95, for a total transaction of $98,419.05. Following the transaction, the insider directly owned 117,103 shares in the company, valued at $9,011,075.85. This represents a 1.08% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Neil Gregory Almstead also recently made the following trade(s):

• On Wednesday, January 7th, Neil Gregory Almstead sold 52 shares of PTC Therapeutics stock. The stock was sold at an average price of $77.48, for a total transaction of $4,028.96.
• On Wednesday, January 7th, Neil Gregory Almstead sold 1,026 shares of PTC Therapeutics stock. The stock was sold at an average price of $77.48, for a total value of $79,494.48.
• On Tuesday, January 6th, Neil Gregory Almstead sold 54 shares of PTC Therapeutics stock. The shares were sold at an average price of $76.95, for a total value of $4,155.30.
• On Monday, November 24th, Neil Gregory Almstead sold 35,572 shares of PTC Therapeutics stock. The stock was sold at an average price of $80.18, for a total value of $2,852,162.96.
• On Tuesday, November 25th, Neil Gregory Almstead sold 71,928 shares of PTC Therapeutics stock. The stock was sold at an average price of $83.44, for a total value of $6,001,672.32.

PTC Therapeutics Trading Down 0.5%

NASDAQ PTCT opened at $76.85 on Friday. The stock’s 50 day moving average is $76.43 and its 200 day moving average is $62.53. PTC Therapeutics, Inc. has a 12 month low of $35.95 and a 12 month high of $87.50. The stock has a market cap of $6.17 billion, a PE ratio of 8.98 and a beta of 0.49.

PTC Therapeutics (NASDAQ:PTCT) last announced its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported $0.20 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.19) by $1.39. The business had revenue of $211.01 million during the quarter, compared to analyst estimates of $177.42 million. PTC Therapeutics had a net margin of 42.25% and a negative return on equity of 194.11%. The company’s revenue was up 7.2% on a year-over-year basis. During the same period last year, the firm posted ($1.39) EPS. On average, analysts forecast that PTC Therapeutics, Inc. will post -4.52 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have commented on the stock. Citigroup increased their price objective on shares of PTC Therapeutics from $50.00 to $75.00 and gave the company a “neutral” rating in a report on Wednesday, November 5th. Wells Fargo & Company increased their price target on PTC Therapeutics from $73.00 to $93.00 and gave the company an “overweight” rating in a research note on Wednesday, November 5th. Wall Street Zen raised PTC Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, January 3rd. Jefferies Financial Group upped their price objective on PTC Therapeutics from $63.00 to $77.00 and gave the stock a “buy” rating in a report on Tuesday, October 28th. Finally, The Goldman Sachs Group raised their target price on shares of PTC Therapeutics from $44.00 to $50.00 and gave the company a “sell” rating in a report on Wednesday, November 5th. Nine investment analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $77.27.

Key Headlines Impacting PTC Therapeutics

Here are the key news stories impacting PTC Therapeutics this week:

• Neutral Sentiment: Analysts maintain a consensus rating of “Hold” on PTCT, signaling muted broker enthusiasm and limited near-term upward catalyst from Wall Street. Article Title
• Neutral Sentiment: PTC reported an inducement grant of 300 restricted stock units for a new non-executive hire under Nasdaq Rule 5635(c)(4); a routine, small hire award with minimal direct financial impact but modest dilution. Article Title
• Negative Sentiment: A company director executed a sizable sale valued at $916,200, a notable insider disposition that can weigh on investor sentiment even if done for personal reasons. Article Title
• Negative Sentiment: Broad insider selling disclosed in SEC Form 4 filings: multiple senior executives (including CEO Matthew B. Klein, CFO Pierre Gravier, EVP Lee Golden, VP Mark Boulding, CAO Christine Utter and others) sold shares in early January. These trades—ranging from small lots to multi-thousand-share sales—represent notable reductions in insider positions and may signal profit-taking or diversification, which can pressure the stock until a clear operational/strategy signal offsets them. Representative filings: SEC Form 4

Hedge Funds Weigh In On PTC Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Smartleaf Asset Management LLC increased its position in shares of PTC Therapeutics by 101.3% during the 3rd quarter. Smartleaf Asset Management LLC now owns 469 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 236 shares during the last quarter. Optiver Holding B.V. boosted its stake in PTC Therapeutics by 96.5% during the third quarter. Optiver Holding B.V. now owns 507 shares of the biopharmaceutical company’s stock worth $31,000 after buying an additional 249 shares during the period. Comerica Bank increased its position in PTC Therapeutics by 868.5% during the third quarter. Comerica Bank now owns 523 shares of the biopharmaceutical company’s stock valued at $32,000 after acquiring an additional 469 shares during the last quarter. IFP Advisors Inc increased its position in PTC Therapeutics by 68.1% during the third quarter. IFP Advisors Inc now owns 765 shares of the biopharmaceutical company’s stock valued at $47,000 after acquiring an additional 310 shares during the last quarter. Finally, PNC Financial Services Group Inc. raised its stake in shares of PTC Therapeutics by 42.1% in the second quarter. PNC Financial Services Group Inc. now owns 995 shares of the biopharmaceutical company’s stock valued at $49,000 after acquiring an additional 295 shares during the period.

PTC Therapeutics Company Profile

PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule and biologic therapies for the treatment of rare genetic disorders. Since its founding in 1998, PTC has dedicated its efforts to addressing high unmet medical needs by targeting underlying genetic causes of disease. The company’s research platform emphasizes mechanisms such as nonsense suppression and RNA modulation, enabling the development of novel treatments for conditions with limited therapeutic options.

Among PTC’s approved products is Translarna (ataluren), a first-in-class therapy designed to treat nonsense mutation Duchenne muscular dystrophy in select markets.